CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced its participation in a $22 million “Roadmap Grant” from the National Institutes of Health (NIH) awarded to leading scientists at UT Southwestern for research on obesity. In the funded research, Alnylam will design, synthesize, and optimize RNAi therapeutic compounds toward disease targets involved in the cause or pathway of obesity discovered by UT Southwestern scientists. Alnylam retains the rights to develop and commercialize RNAi therapeutics from the research effort.
